MedPath

Safety and Efficacy of Study Drug Versus Placebo for Negative Symptoms of Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Registration Number
NCT00063297
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Brief Summary

This study is to determine the efficacy (how well the drug works), safety, and side effects of the study medication compared to placebo in the treatment of the negative symptoms of schizophrenia in adults.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
180
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (28)

Birmingham Psychiatry Pharmaceutical Studies, Inc.

🇺🇸

Birmingham, Alabama, United States

IPR

🇺🇸

Cerritos, California, United States

Synergy Clinical Research

🇺🇸

Chula Vista, California, United States

Optimum Health Services

🇺🇸

La Mesa, California, United States

Sierra Vista Hospital

🇺🇸

Sacramento, California, United States

Clinical Innovations

🇺🇸

Santa Ana, California, United States

Research Strategies

🇺🇸

Torrance, California, United States

University of Colorado

🇺🇸

Denver, Colorado, United States

Psychiatric Institute of Washington

🇺🇸

Washington, DC, District of Columbia, United States

Berma Research Group

🇺🇸

Hialeah, Florida, United States

Scroll for more (18 remaining)
Birmingham Psychiatry Pharmaceutical Studies, Inc.
🇺🇸Birmingham, Alabama, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.